Therapeutic Effect of Human iPS-Cell-Derived Myeloid Cells Expressing IFN-β against Peritoneally Disseminated Cancer in Xenograft Models

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Koba, Chihiro ^a,b   Haruta, Miwa ^a,b   Matsunaga, Yusuke ^a,b   Matsumura, Keiko ^a,b   Haga, Eriko ^a,b   Sasaki, Yuko ^a,b   Ikeda, Tokunori ^a,b   Takamatsu, Koutaro ^a,b   Nishimura, Yasuharu ^a   Senju, Satoru ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL INFILTRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PANCREAS CANCER; PERITONEUM CANCER; PLURIPOTENT STEM CELL; STOMACH CANCER; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INJECTIONS, INTRAPERITONEAL; INTERFERON-BETA; MACROPHAGES; MICE; MICE, SCID; MYELOID CELLS; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; PERITONEUM; RECEPTOR, ERBB-2; SINGLE-CHAIN ANTIBODIES; STEM CELL TRANSPLANTATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

IPS; MUS;

EID: 84879465752     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067567     Document Type: Article

References (43)

1. Lewis CE, Pollard JW, (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612.
2. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A, (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25: 315-322.
3. Bonnotte B, Larmonier N, Favre N, Fromentin A, Moutet M, et al. (2001) Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol 167: 5077-5083.
4. Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, et al. (2012) Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci U S A 109: 2066-2071.
5. Andreesen R, Scheibenbogen C, Brugger W, Krause S, Meerpohl HG, et al. (1990) Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 50: 7450-7456.
6. Andreesen R, Hennemann B, Krause SW, (1998) Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 64: 419-426.
7. Klimp AH, de Vries EG, Scherphof GL, Daemen T, (2002) A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol 44: 143-161.
8. Monnet I, Breau JL, Moro D, Lena H, Eymard JC, et al. (2002) Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Chest 121: 1921-1927.
9. Baron-Bodo V, Doceur P, Lefebvre ML, Labroquere K, Defaye C, et al. (2005) Anti-tumor properties of human-activated macrophages produced in large scale for clinical application. Immunobiology 210: 267-277.
10. Takahashi K, Yamanaka S, (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
11. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
12. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
13. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, et al. (2008) Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141-146.
14. Kaufman DS, (2009) Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 114: 3513-3523.
15. Sharkis SJ, Jones RJ, Civin C, Jang YY, (2012) Pluripotent stem cell-based cancer therapy: promise and challenges. Sci Transl Med 4: 127-129.
16. Moore KJ, Fabunmi RP, Andersson LP, Freeman MW, (1998) In vitro-differentiated embryonic stem cell macrophages: a model system for studying atherosclerosis-associated macrophage functions. Arterioscler Thromb Vasc Biol 18: 1647-1654.
17. Lindmark H, Rosengren B, Hurt-Camejo E, Bruder CE, (2004) Gene expression profiling shows that macrophages derived from mouse embryonic stem cells is an improved in vitro model for studies of vascular disease. Exp Cell Res 300: 335-344.
18. Odegaard JI, Vats D, Zhang L, Ricardo-Gonzalez R, Smith KL, et al. (2007) Quantitative expansion of ES cell-derived myeloid progenitors capable of differentiating into macrophages. J Leukoc Biol 81: 711-719.
19. Choi KD, Vodyanik MA, Slukvin I, (2009) Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors. J Clin Invest 119: 2818-2829.
20. Senju S, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, et al. (2009) Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Stem Cells 27: 1021-1031.
21. Senju S, Haruta M, Matsumura K, Matsunaga Y, Fukushima S, et al. (2011) Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther 18: 874-883.
22. Karlsson KR, Cowley S, Martinez FO, Shaw M, Minger SL, et al. (2008) Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3. Exp Hematol 36: 1167-1175.
23. Grigoriadis AE, Kennedy M, Bozec A, Brunton F, Stenbeck G, et al. (2010) Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood 115: 2769-2776.
24. Klimchenko O, Di Stefano A, Geoerger B, Hamidi S, Opolon P, et al. (2011) Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. Blood 117: 3065-3075.
25. Haruta M, Tomita Y, Yuno A, Matsumura K, Ikeda T, et al. (2012) TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. Gene Ther. Epub ahead of print.
26. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-717.
27. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM, (1998) Development of a self-inactivating lentivirus vector. J Virol 72: 8150-8157.
28. Gravalos C, Jimeno A, (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529.
29. Kuniyasu H, Yasui W, Kitahara K, Naka K, Yokozaki H, et al. (1997) Growth inhibitory effect of interferon-beta is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1 in a human gastric carcinoma cell line. Cell Growth Differ 8: 47-52.
30. Shyu RY, Su HL, Yu JC, Jiang SY, (2000) Direct growth suppressive activity of interferon-alpha and-gamma on human gastric cancer cells. J Surg Oncol 75: 122-130.
31. Pace JL, Russell SW, Torres BA, Johnson HM, Gray PW, (1983) Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol 130: 2011-2013.
32. Celada A, Gray PW, Rinderknecht E, Schreiber RD, (1984) Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med 160: 55-74.
33. Pace JL, Russell SW, LeBlanc PA, Murasko DM, (1985) Comparative effects of various classes of mouse interferons on macrophage activation for tumor cell killing. J Immunol 134: 977-981.
34. Adam Z, Vorlícek J, (1994) Therapeutic use of interferon beta. Vnitr Lek 40: 329-333.
35. Roukos DH, (2000) Current status and future perspectives in gastric cancer management. Cancer Treat Rev 26: 243-255.
36. Kim DY, Joo JK, Park YK, Ryu SY, Kim YJ, et al. (2006) Prognostic factors in gastric carcinoma with peritoneal dissemination. Acta Chir Belg 106: 665-668.
37. Yonemura Y, Endo Y, Obata T, Sasaki T, (2007) Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites. Cancer Sci 98: 11-18.
38. Li D, Abbruzzese JL, (2010) New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res 16: 4313-4318.
39. Neefjes JJ, Momburg F, Hammerling GJ, (1993) Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 261: 769-771.
40. Loyer V, Fontaine P, Pion S, Hetu F, Roy DC, et al. (1999) The in vivo fate of APCs displaying minor H antigen and/or MHC differences is regulated by CTLs specific for immunodominant class I-associated epitopes. J Immunol 163: 6462-6467.
41. Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F, (2000) CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 164: 3095-3101.
42. Matsunaga Y, Fukuma D, Hirata S, Fukushima S, Haruta M, et al. (2008) Activation of antigen-specific cytotoxic T lymphocytes by beta2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells. J Immunol 181: 6635-6643.
43. Bacik I, Cox JH, Anderson R, Yewdell JW, Bennink JR, (1994) TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide. J Immunol 152: 381-387.